Stockscreener 앱 받기
30.67
10.47%
-3.62
전일 마감가:
$34.29
열려 있는:
$30.81
하루 거래량:
7.49M
Relative Volume:
2.02
시가총액:
$1.68B
수익:
$14.34M
순이익/손실:
$-199.00M
주가수익비율:
-7.824
EPS:
-3.92
순현금흐름:
$-183.51M
1주 성능:
-56.14%
1개월 성능:
-44.10%
6개월 성능:
+107.85%
1년 성능:
+452.16%
1일 변동 폭
$28.50
$32.49
1주일 범위
$22.85
$70.88
52주 변동 폭
$5.35
$71.50
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
30.64 | 2.11B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.37 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.93 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.31 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.08 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.73 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
uniQure N.V. Securities Lawsuit Investigation - Claim Depot
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy - Benzinga
uniQure (NASDAQ:QURE) Shares Gap DownHere's Why - MarketBeat
uniQure (QURE) Analyst Rating Update: Goldman Sachs Lowers Price Target | QURE Stock News - GuruFocus
uniQure (QURE) Shares Drop Over 15% Amid Market Shifts - GuruFocus
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - FinancialContent
UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE) - Seeking Alpha
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $70 - 富途牛牛
William Blair Downgrades uniQure N.V to Market Perform From Outperform - MarketScreener
uniQure (QURE) Downgraded by William Blair to Market Perform | Q - GuruFocus
uniQure stock price target lowered to $70 at H.C. Wainwright on FDA setback - Investing.com Nigeria
uniQure (QURE) Price Target Lowered by HC Wainwright & Co. | QUR - GuruFocus
uniQure (QURE) Downgraded by William Blair Amid Uncertainty Over AMT-130 - GuruFocus
William Blair Downgrades UniQure NV(QURE.US) to Hold Rating - 富途牛牛
Predicting uniQure N.V. trend using moving averagesChart Signals & Real-Time Chart Pattern Alerts - newser.com
Volatility clustering patterns for uniQure N.V.Dip Buying & Long-Term Capital Growth Strategies - newser.com
Risk adjusted return profile for uniQure N.V. analyzedJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Is uniQure N.V. stock a bargain at current levelsJuly 2025 WrapUp & Precise Entry and Exit Recommendations - newser.com
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data - CGTLive®
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors Should Contact the Firm to Potentially Recover Losses - Supply Chain Digital Magazine
FDA’s rebuff of uniQure raises uncertainty over external control standards - BioCentury
How FDA’s Revised Stance on AMT-130 Data Has Changed uniQure’s (QURE) Investment Story - simplywall.st
uniQure (QURE) Maintains Buy Rating as Chardan Capital Lowers Pr - GuruFocus
UniQure Reeling As FDA Reverses Stance On Accelerated Approval For AMT-130 - Citeline News & Insights
UniQure Shares Dive After ‘Surprising’ Pivot by FDA on Drug Data - Bloomberg.com
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors ... - Bluefield Daily Telegraph
QURE Investor ALERT: Block & Leviton Investigating uniQure - GlobeNewswire
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC - GlobeNewswire
Why UniQure Stock Is Plunging TodayuniQure (NASDAQ:QURE) - Benzinga
uniQure N.V. (QURE) Stock: Plunges 57% After Unexpected FDA Setback on AMT-130 - CoinCentral
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - The AI Journal
uniQure (QURE) Shares Plunge Over 50% - GuruFocus
uniQure (QURE) Faces Setback with FDA on AMT-130 BLA Submission - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy - Reuters
UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enoughhere's what i - The Economic Times
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - Stocktwits
uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - MSN
uniQure stock falls after FDA feedback on gene therapy application - Seeking Alpha
uniQure (QURE) Faces FDA Reversal on AMT-130 Phase 1/2 Data - GuruFocus
Uniqure stock plunges after FDA rejects company’s clinical data for Huntington's therapy - Proactive financial news
uniQure (QURE) Shares Plummet Over 57% - GuruFocus
UniQure (QURE) Stock: Biotech Plunges 67% After FDA Reverses Position on Gene Therapy Data - parameter.io
UniQure Shares Fall Sharply as Trading Resumes After Volatility Halt - MarketScreener
uniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – QURE - The Globe and Mail
UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. -- Barrons.com - 富途牛牛
Top Premarket Decliners - 富途牛牛
How analysts rate uniQure N.V. stock today2025 Analyst Calls & Real-Time Buy Zone Alerts - newser.com
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy - MSN
UniQure’s FDA submission for its Huntington’s disease therapy thrown into question - statnews.com
UniQure Shares Fall Pre-Bell After FDA Raises Questions on Huntington's Disease Therapy Data - MarketScreener
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Uniqure N V 주식 (QURE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
1.09%
0.46%
자본화:
|
볼륨(24시간):